详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC pts with Oligometastatic or Oligoprogressive Liver Metastases

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

单位： [1]Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China [2]Henan Canc Hosp, Med, Zhengzhou, Henan, Peoples R China [3]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China

出处：

DOI：

ISSN：

关键词： Liver Metastasis EGFR mutation non-small cell lung cancer

语种：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2016]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

最新[2024]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 20.8 最新[2024版] 18.4 最新五年平均 6.595 出版当年[2016版] 5.983 出版当年五年平均 5.04 出版前一年[2015版] 10.34 出版后一年[2017版]

第一作者：

第一作者单位： [1]Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report [2]Detection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Circulating tumour (ct) DNA analysis across 3 platforms [3]A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions [4]Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China [5]Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer [6]Pilot Study on the Tumor Immune Microenvironment Between Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) [7]Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer [8]Immunotherapy in advanced non-small-cell lung cancer withEGFRmutations [9]PSM Analysis Results from REFRACT: A Multi-Center Cohort Study Investigating the Treatment Patterns in EGFR-Mutant Unresectable LA- NSCLC [10]Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: Interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS study